Compare Cincinnati Financial Corporation (CINF) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Cincinnati Financial Corporation trades at $173.45 (market cap $26.68B), while Recursion Pharmaceuticals Inc trades at $3.33 (market cap $1.78B). The key difference: Cincinnati Financial Corporation is far larger — about 15× Recursion Pharmaceuticals Inc's market cap, and Cincinnati Financial Corporation pays a 2.16% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CINF | RXRX | |
|---|---|---|
Market Cap | $26.68B | $1.78B |
Sector | Financials | Health |
52-Week High | $192.03 | $6.79 |
52-Week Low | $149.79 | $2.84 |
Enterprise Value | $25.80B | $1.30B |
Dividend Yield | 2.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $176.86, down 1.22% on the day, with a bearish technical signal but strong fundamentals including a P/E of 8.35 and ROE of 21.48%. Recent Q2 2026 earnings missed estimates at $1.43 per share versus $1.84 expected, though revenue grew year-over-year. The company maintains robust cash flow, with 2025 operating cash flow at $3.11 billion, and a consistent dividend history, including a recent $0.94 payout.
Outlook is mixed: valuation appears attractive with analyst consensus price target of $195, but near-term headwinds include catastrophe losses and commercial lines weakness. Long-term growth is supported by premium expansion and investment income, though investors face risks from underwriting volatility and economic sensitivity.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
